Ariddad Therapeutics

The first-in-its-class medicinal drug with double action

OWNER

Miguel Garcia-Toscano (See Profile)


Sector

Biotech

Stage

In vivo, proof of concept

Country

Spain

First drug with tolerogenic/anti-inflammatory and tissue regenerative action

Our technology is protected.

The partners/founders represent a strong/experienced and compensated team

The LRH-1/SHP agonists can be used for the treatment of other indications with higher prevalence

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck

PRE-MONEY VALUATION: 25M€

Post-money valuation = 0,5 M€  x ( (100 % shares + 2% shares) / 2 % shares )   = 25,5 M€
Pre-money valuation = 25,5 M€ – 0,5 M€ =  25 M€

Under evaluation at least till: 2nd November

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar